↓ Skip to main content

Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms

Overview of attention for article published in Molecular Cancer, March 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (84th percentile)
  • High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

patent
4 patents
wikipedia
1 Wikipedia page

Citations

dimensions_citation
94 Dimensions

Readers on

mendeley
89 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms
Published in
Molecular Cancer, March 2013
DOI 10.1186/1476-4598-12-19
Pubmed ID
Authors

Kerstin Maria Kampa-Schittenhelm, Michael Charles Heinrich, Figen Akmut, Hartmut Döhner, Konstanze Döhner, Marcus Matthias Schittenhelm

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 89 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 1%
United States 1 1%
Unknown 87 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 16 18%
Student > Master 13 15%
Student > Bachelor 12 13%
Student > Ph. D. Student 11 12%
Student > Postgraduate 6 7%
Other 14 16%
Unknown 17 19%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 19 21%
Agricultural and Biological Sciences 19 21%
Medicine and Dentistry 16 18%
Pharmacology, Toxicology and Pharmaceutical Science 6 7%
Chemistry 4 4%
Other 6 7%
Unknown 19 21%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 September 2023.
All research outputs
#3,919,343
of 25,998,826 outputs
Outputs from Molecular Cancer
#328
of 1,960 outputs
Outputs of similar age
#31,732
of 211,690 outputs
Outputs of similar age from Molecular Cancer
#2
of 17 outputs
Altmetric has tracked 25,998,826 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,960 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.0. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 211,690 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.